Solcitinib-GSK-2586184-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESolcitinibCat. No.: HY-16755CAS No.: 1206163-45-2Synonyms: GSK-2586184; GLPG-0778分式: CHNO分量: 389.45作靶点: JAK作通路: Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month

2、溶解性数据体外实验 DMSO : 20 mg/mL (51.35 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.5677 mL 12.8386 mL 25.6772 mL5 mM 0.5135 mL 2.5677 mL 5.1354 mL10 mM 0.2568 mL 1.2839 mL 2.5677 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Solcitinib种可服的，竞争

3、性的，有效的，选择性的 JAK1 抑制剂，IC50 值为 9.8 nM，对其选择性是对JAK2，JAK3 和 TYK2 的 11，55 和 23 倍；Solcitinib 可于银屑病的研究。IC50 & Target JAK19.8 nM (IC50)1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE体外研究 Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55-and 2

4、3-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research ofmoderate-to-severe plaque-type psoriasis 1.REFERENCES1. Ludbrook VJ, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol. 2016 May;174(5):985-95.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792;Fax